The start of commercial production is scheduled for May (ANSA)
The Russian Fund for Direct Investments (Rdif) has announced that it has reached an agreement with the company Shenzhen Yuanxing Gene-Tech for the production in China of more than 60 million doses of the Russian Sputnik V vaccine against Covid-19. Tass reports it. "The volume produced - says Rdif - will allow the vaccination of over 30 million people. The start of commercial production is schedule
The Russian Fund for Direct Investments (Rdif) has announced that it has reached an agreement with the company Shenzhen Yuanxing Gene-Tech for the production in China of more than 60 million doses of the Russian Sputnik V vaccine against Covid-19.
Tass reports it.
"The volume produced - says Rdif - will allow the vaccination of over 30 million people. The start of commercial production is scheduled for May of this year".